BioPharmSignal logoBioPharmSignal

Biotech News

Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer

Syndax Pharmaceuticals (SNDX)Syndax PharmaceuticalsCommercial

- Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition - NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the

Related news

SNDXSyndax Pharmaceuticals2026-10-30 13:01 EST

Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases

SNDXSyndax Pharmaceuticals2026-10-15 20:01 EST

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

RVMDRevolution Medicines2026-10-27 20:05 EST

Revolution Medicines to Participate in November 2026 Investor Conferences

FATEFate Therapeutics2026-10-12 11:00 EST

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

KPTIKaryopharm Therapeutics2026-10-01 20:05 EST

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REPLReplimune Group2026-10-01 20:01 EST

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

SNYSanofi2026-10-12 16:05 EST

Sanofi: Information concerning the total number of voting rights and shares – September 2026

KURAKura Oncology2026-10-07 11:15 EST

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

KURAKura Oncology2026-11-03 11:58 EST

Kura Oncology to Report Third Quarter Financial Results on November 10

BMYBMYBristol-Myers Squibb Company2026-10-29 10:59 EST

Bristol Myers Squibb Reports Third Quarter Financial Results for 2026

View all latest news

Syndax Pharmaceuticals

Commercial Oncology Portfolio Syndax Pharmaceuticals develops and commercializes therapies for genetically defined leukemias and immune-mediated complications of transplantation. Its commercial portfolio is built around Revuforj and Niktimvo. Revuforj Revuforj, or revumenib, is a menin inhibitor used in acute leukemias with susceptible...

Recent company news

SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

SNDXSyndax Pharmaceuticals2026-11-04 14:00 EST

Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026

SNDXSyndax Pharmaceuticals2026-11-02 21:01 EST

Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer

SNDXSyndax Pharmaceuticals2026-11-02 21:01 EST

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

SNDXSyndax Pharmaceuticals2026-10-30 13:01 EST

Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases

Stock data

Close
9.37 USD
Market cap
1.63B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States